Contact Us: 01282 426380
KM Financial Solutions | UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents
22290
post-template-default,single,single-post,postid-22290,single-format-standard,qode-quick-links-1.0,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-child-theme-ver-1.0.0,qode-theme-ver-11.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.2.1,vc_responsive
 

UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

12 Jul UPDATE 2-U.S. court denies Jazz Pharma bid to revive narcolepsy drug patents

Posted at 17:53h in News by
0 Likes
A U.S. appeals court on Friday ruled
invalid patents owned by Jazz Pharmaceuticals PLC
covering its narcolepsy drug Xyrem, giving Amneal
Pharmaceuticals Inc a boost in its effort to launch a
generic version of the medicine.

No Comments

Sorry, the comment form is closed at this time.